Robert Kennedy Jr. will keep his share of any windfall from litigation against Merck (MRK) even if he becomes Donald Trump’s top U.S. health official, Oliver Barnes of The Financial Times reports, citing ethics records. In an ethics record recently published, Kennedy said he would keep any potential winnings from a case brough by Wisner Baum against Merck’s Gardasil vaccine, which prevents human papillomavirus. Kennedy said he was entitled to keep interests in cases that did not involve the U.S. or in which the state did not have a “direct and substantial interest.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- RFK Jr Will Keep Merck (NYSE:MRK) Vaccine Lawsuit Fees if Confirmed Health Secretary
- Edgewise Therapeutics promotes Behrad Derakhshan to COO
- Merck price target lowered to $113 from $123 at Morgan Stanley
- Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations
- Dow Jones Jumps Alongside Treasury Yields Recovery